nach oben

Der Nervenarzt

Erschienen in:

01.06.2006 | Übersichten

Antikoagulanzienassoziierte Hirnblutungen

verfasst von: Dr. H. B. Huttner, E. Jüttler, A. Hug, M. Köhrmann, P. D. Schellinger, T. Steiner

Erschienen in: Der Nervenarzt | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine lebensbedrohliche intrakranielle Blutung (ICB) ist die schwerwiegendste Komplikation einer Therapie mit oralen Antikoagulanzien (OAT). Die zunehmende Verwendung von OAT resultiert in einer Steigerung der Inzidenz von ICB. Die Mortalität ist annähernd 65% und Patienten, die überleben, sind meist schwer behindert. Während in letzter Zeit erhebliche Fortschritte bei der Behandlung der spontanen ICB erreicht wurden, bleiben weiterhin die Unterschiede in der Pathophysiologie und im Akutmanagement von antikoagulanzienassoziierter ICB (OAT-ICB) und spontaner ICB ungeklärt. Deshalb sind effektive Behandlungsstrategien essenziell, um das Outcome zu verbessern. Diese Arbeit gibt einen Überblick über die Epidemiologie, Pathophysiologie und akute Behandlungsstrategien von OAT-ICB und diskutiert offene Fragen insbesondere hinsichtlich neuer medikamentöser Ansätze.

Anonymous (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 156:409–416CrossRefPubMed

Anonymous (1998) Guidelines on oral anticoagulation: third edition. Br J Haematol 101:374–387CrossRefPubMed

Anonymous (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 42:857–865CrossRefPubMed

Anonymous (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRefPubMed

Albers GW, Diener HC, Frison L et al. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293:690–698CrossRefPubMed

Ananthasubramaniam K, Beattie JN, Rosman HS et al. (2001) How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 119:478–484CrossRefPubMed

Ansell J, Hirsh J, Dalen J et al. (2001) Managing oral anticoagulant therapy. Chest 119:22S–38SCrossRefPubMed

Babikian VL, Kase CS, Pessin MS et al. (1988) Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke 19:407–408

Bamford J, Sandercock P, Dennis M et al. (1990) A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 53:16–22PubMed

10.

Bertram M, Bonsanto M, Hacke W et al. (2000) Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 247:209–214CrossRefPubMed

11.

Berwaerts J, Dijkhuizen RS, Robb OJ et al. (2000) Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke 31:2558–2562PubMed

12.

Boffard KD, Riou B, Warren B et al. (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59:8–18PubMed

13.

Boulis NM, Bobek MP, Schmaier A et al. (1999) Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 45:1113–1119CrossRefPubMed

14.

Broderick JP, Brott T, Tomsick T et al. (1992) The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 326:733–736PubMed

15.

Broderick JP, Brott TG, Duldner JE et al. (1993) Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24:987–993PubMed

16.

Brody DL, Aiyagari V, Shackleford AM et al. (2005) Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2:263–267CrossRefPubMed

17.

Brott T, Broderick J, Kothari R et al. (1997) Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28:1–5PubMed

18.

Butler AC, Tait RC (1998) Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev 12:35–44CrossRefPubMed

19.

Cannegieter SC, Rosendaal FR, Wintzen AR et al. (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17CrossRefPubMed

20.

Dandapani BK, Suzuki S, Kelley RE et al. (1995) Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 26:21–24PubMed

21.

Daverat P, Castel JP, Dartigues JF et al. (1991) Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke 22:1–6PubMed

22.

Deveras RA, Kessler CM (2002) Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884–888PubMed

23.

Erhardtsen E, Nony P, Dechavanne M et al. (1998) The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 9:741–748PubMed

24.

Fernandes HM, Gregson B, Siddique S et al. (2000) Surgery in intracerebral hemorrhage. The uncertainty continues. Stroke 31:2511–2516PubMed

25.

Fiessinger JN, Huisman MV, Davidson BL et al. (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293:681–689CrossRefPubMed

26.

Fihn SD, McDonell M, Martin D et al. (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 118:511–520PubMed

27.

Flibotte JJ, Hagan N, O’Donnell J et al. (2004) Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63:1059–1064PubMed

28.

Fogelholm R, Eskola K, Kiminkinen T et al. (1992) Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 55:1121–1124

29.

Franke CL, de Jonge J, van Swieten JC et al. (1990) Intracerebral hematomas during anticoagulant treatment. Stroke 21:726–730PubMed

30.

Fredriksson K, Norrving B, Stromblad LG (1992) Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 23:972–977PubMed

31.

Freeman WD, Brott TG, Barrett KM et al. (2004) Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79:1495–1500PubMed

32.

Fregin A, Rost S, Wolz W et al. (2002) Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood 100:3229–3232CrossRefPubMed

33.

Gebel JM Jr, Jauch EC, Brott TG et al. (2002) Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 33:2636–2641CrossRefPubMed

34.

Gilstad CW (2003) Anaphylactic transfusion reactions. Curr Opin Hematol 10:419–423CrossRefPubMed

35.

Go AS, Hylek EM, Phillips KA et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375CrossRefPubMed

36.

Gorter JW (1999) Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 53:1319–1327PubMed

37.

Hanley JP (2004) Warfarin reversal. J Clin Pathol 57:1132–1139CrossRefPubMed

38.

Hart RG (2000) What causes intracerebral hemorrhage during warfarin therapy? Neurology 55:907–908PubMed

39.

Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26:1471–1477PubMed

40.

Hellstern P (1999) Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 95:S7–S12CrossRefPubMed

41.

Hellstern P, Halbmayer WM, Kohler M et al. (1999) Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 95:S3–S6CrossRefPubMed

42.

Hellstern P, Muntean W, Schramm W et al. (2002) Practical guidelines for the clinical use of plasma. Thromb Res 107(Suppl 1):S53–S57

43.

Hirsh J, Dalen J, Anderson DR et al. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:8S–21SCrossRefPubMed

44.

Hug A, Aschoff A, Schwab S (2004) [Spontaneous intracerebral hemorrhages]. Nervenarzt 75:953–961CrossRefPubMed

45.

Hylek EM, Go AS, Chang Y et al. (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026CrossRefPubMed

46.

Hylek EM, Singer DE (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897–902PubMed

47.

Juvela S (1995) Risk factors for impaired outcome after spontaneous intracerebral hemorrhage. Arch Neurol 52:1193–1200

48.

Kazui S, Minematsu K, Yamamoto H et al. (1997) Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 28:2370–2375PubMed

49.

Kazui S, Naritomi H, Yamamoto H et al. (1996) Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 27:1783–1787PubMed

50.

Leira R, Davalos A, Silva Y et al. (2004) Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 63:461–467PubMed

51.

Lisk DR, Pasteur W, Rhoades H et al. (1994) Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 44:133–139PubMed

52.

Makris M, Greaves M, Phillips WS et al. (1997) Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77:477–480PubMed

53.

Mathiesen T, Benediktsdottir K, Johnsson H et al. (1995) Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 91:208–214

54.

Mayer SA (2003) Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 34:224–229CrossRefPubMed

55.

Mayer SA, Brun NC, Begtrup K et al. (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352:777–785CrossRefPubMed

56.

Mayer SA, Brun NC, Broderick J et al. (2005) Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 36:74–79CrossRefPubMed

57.

Mendelow AD, Gregson BA, Fernandes HM et al. (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365:387–397PubMed

58.

Naff NJ, Carhuapoma JR, Williams MA et al. (2000) Treatment of intraventricular hemorrhage with urokinase: effects on 30-Day survival. Stroke 31:841–847PubMed

59.

Naff NJ, Hanley DF, Keyl PM et al. (2004) Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 54:577–584CrossRefPubMed

60.

Nelson R (2005) Novel MMP inhibitor has potential for treatment of stroke. Lancet Neurol 4:530CrossRef

61.

Nilsson OG, Lindgren A, Brandt L et al. (2002) Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg 97:531–536PubMed

62.

O’Donnell HC, Rosand J, Knudsen KA et al. (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 342:240–245CrossRefPubMed

63.

Oldenburg J, von Brederlow B, Fregin A et al. (2000) Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 84:937–941PubMed

64.

Palareti G, Leali N, Coccheri S et al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428CrossRefPubMed

65.

Phan TG, Koh M, Vierkant RA et al. (2000) Hydrocephalus is a determinant of early mortality in putaminal hemorrhage. Stroke 31:2157–2162PubMed

66.

Phan TG, Koh M, Wijdicks EF (2000) Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 57:1710–1713

67.

Pindur G, Morsdorf S, Schenk JF et al. (1999) The overdosed patient and bleedings with oral anticoagulation. Semin Thromb Hemost 25:85–88PubMed

68.

Pomper GJ, Wu Y, Snyder EL (2003) Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 10:412–418CrossRefPubMed

69.

Radberg JA, Olsson JE, Radberg CT (1991) Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 22:571–576PubMed

70.

Revesz T, Ghiso J, Lashley T et al. (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885–898PubMed

71.

Roob G, Schmidt R, Kapeller P et al. (1999) MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 52:991–994PubMed

72.

Rosand J, Eckman MH, Knudsen KA et al. (2004) The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164:880–884CrossRefPubMed

73.

Rosand J, Hylek EM, O’Donnell HC et al. (2000) Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 55:947–951PubMed

74.

Rost S, Fregin A, Ivaskevicius V et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541CrossRefPubMed

75.

Sansing LH, Kaznatcheeva EA, Perkins CJ et al. (2003) Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment. J Neurosurg 98:985–992PubMed

76.

Schellinger PD, Fiebach JB, Hoffmann K et al. (2003) Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke 34:1674–1679CrossRefPubMed

77.

Seitz R, Dodt J (1999) Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res 95:S19–S23CrossRefPubMed

78.

Sjoblom L, Hardemark HG, Lindgren A et al. (2001) Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 32:2567–2574PubMed

79.

Sorensen B, Johansen P, Nielsen GL et al. (2003) Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 14:469–477CrossRefPubMed

80.

Tuhrim S, Dambrosia JM, Price TR et al. (1988) Prediction of intracerebral hemorrhage survival. Ann Neurol 24:258–263CrossRefPubMed

81.

Turpie AG, Gent M, Laupacis A et al. (1993) A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329:524–529CrossRefPubMed

82.

van der Meer FJ, Rosendaal FR, Vandenbroucke JP et al. (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153:1557–1562CrossRefPubMed

83.

Vasishta S, Toor F, Johansen A et al. (2001) Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people. Arch Gerontol Geriatr 33:219–226CrossRefPubMed

84.

Wang J, Tsirka SE (2005) Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128:1622–1633CrossRefPubMed

85.

Wijdicks EF, Schievink WI, Brown RD et al. (1998) The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 42:769–773CrossRefPubMed

86.

Yasaka M, Minematsu K, Naritomi H et al. (2003) Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 89:278–283PubMed

87.

Yasaka M, Minematsu K, Yamaguchi T (2001) Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40:1183–1188PubMed

88.

Zazulia AR, Diringer MN, Videen TO et al. (2001) Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 21:804–810CrossRefPubMed

Titel: Antikoagulanzienassoziierte Hirnblutungen
verfasst von: Dr. H. B. Huttner
E. Jüttler
A. Hug
M. Köhrmann
P. D. Schellinger
T. Steiner
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 6/2006
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-006-2063-5

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antikoagulanzienassoziierte Hirnblutungen

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Miller-Fisher-Syndrom

Vergleich von Früh- und Spätrehabilitation bei zerebral geschädigten Patienten mit Gesichtsfelddefekten

Mitteilungen der DGPPN 6/06

Retropharyngeale Entzündung unter dem klinischen Bild einer Meningitis

Rezidivierendes reversibles posteriores Leukenzephalopathiesyndrom unter Chemotherapie mit Cisplatin und 5-Fluorouracil

Neurophysiologische und Bildgebungsstudien beim Restless-legs-Syndrom und bei periodischen Beinbewegungen

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein